Alloxan as a better option than streptozotocin for studies involving painful diabetic neuropathy

• Published in: Journal of pharmacological and toxicological methods Vol. 112; p. 107090
• Main Authors: Rodrigues, Paulla Vieira, Lemos, Bruna Moreira Silva, Silva, Maria Vitoria da, de Campos Lima, Taís, Santos, Débora de Oliveira, Lemes, Júlia Borges Paes, Lotufo, Celina Monteiro da Cruz
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-11-2021
• Subjects: Alloxan; Animal model; Diabetes; Method; Pain; Painful diabetic neuropathy; Streptozotocin; Alloxan; Animal model; Pain; Diabetes; Method; Painful diabetic neuropathy; Streptozotocin
• ISSN: 1056-8719; 1873-488X
• DOI: 10.1016/j.vascn.2021.107090

Previous data indicate that the diabetogenic substance streptozotocin might act in nociceptive neurons changing the sensory signal, regardless of hyperglycemia. In the present article the effects of streptozotocin were compared with another diabetogenic drug, alloxan, for diabetes induction in rats. A possible direct effect of these drugs was tested by means of in vivo experiments and in vitro assays using cultured primary nociceptive neurons. Streptozotocin (17.5 and 35 mg/kg), alloxan (15 and 30 mg/kg) or vehicle were injected in adult male rats and the animal groups were separated according to glycemic levels. Body mass, glycemia and paw mechanical sensitivity were evaluated for 5 weeks. Streptozotocin caused an increase in mechanical sensitivity in both hyperglycemic and normoglycemic rats, while alloxan induced mechanical sensitization only in hyperglycemic animals. Injection of both substances induced local inflammation at rat paws; however, only streptozotocin caused significant mechanical sensitization when injected near to sensory neurons at the dorsal root ganglia. Also, streptozotocin treatment induced a reduction in intracellular calcium levels and inhibited capsaicin induced calcium transients and membrane depolarization. Alloxan did not affect calcium levels or membrane potential in primary nociceptive neurons. These findings suggest that alloxan might be a better option for animal studies regarding painful diabetic neuropathy as streptozotocin directly affects nociceptive neurons, probably by modulating TRPV1 channel activation.